MDM2 promoted T cell-mediated anti-tumor immunity by preventing c-Cbl-mediated STAT5 degradation; targeting the p53-MDM2 interaction with a pharmacological agent (APG-115) augmented MDM2 in T cells, boosted T cell immunity, and synergized with cancer immunotherapy (Zhou et al., 2021). The gene discussed is TP53; the disease is neoplasm.